THE MARK FOUNDATION FOR CANCER RESEARCH (US) LTD (EIN 364825921) - Form 990 Financial Analysis & Trantor Score

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2015

Legal Domicile

Principal Officer

RYAN SCHOENFELD

Phone

6468665950

Tax Period

2024-01-01 to 2024-12-31

THE MARK FOUNDATION FOR CANCER RESEARCH (US) LTD, founded in 2015, is a mid-sized nonprofit in the Diseases & Disorders sector that reported $44.8M in total revenue in fiscal year 2024. Revenue grew 9% year-over-year, indicating healthy expansion. The organization ran a surplus of $8.7M, a strong 19% operating margin.

Mission

ACCELERATE RESEARCH TO TRANSFORM PREVENTION, DIAGNOSIS AND TREATMENT OF CANCER.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2024)

Revenue Breakdown

Contributions & Grants $44,393,676

Program Service Revenue $0

Investment Income $409,872

Other Revenue $-30,647

TOTAL REVENUE $44,772,901

Expense Breakdown

Grants Paid $30,533,067

Salaries & Benefits $2,662,168

Fundraising Expenses $1,015,545

Program Expenses $33,898,449

Other Expenses $2,871,515

TOTAL EXPENSES $36,066,750

Year-over-Year Comparison

	2024	2023	Change
Revenue	$44,772,901	$40,937,632	+0.1%
Expenses	$36,066,750	$35,209,497	+0.0%
Net Income	$8,706,151	$5,728,135	+0.5%

Key Indicators

✓ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✓ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

Volunteers

Governance Policies

✓ Conflict of Interest Policy

✓ Whistleblower Policy

✓ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

$1,337,080

Total Directors

$570,000

Key Employees

$348,729

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
ALEX KNASTER	DIRECTOR	1.00	Director	$0	$0	$0
ROSS LEVINE	DIRECTOR	1.00	Director	$10,000	$0	$10,000
NICOLA MENDEHLSON	DIRECTOR	1.00	Director	$0	$0	$0
PAUL POSPISIL	DIRECTOR	1.00	Director	$0	$0	$0
OTMAR D WIESTLER	DIRECTOR	1.00	Director	$0	$0	$0
RAYMOND DUBOIS	EXECUTIVE CHAIRMAN OF THE BOARD	24.00	Officer Director	$560,000	$0	$560,000
RYAN SCHOENFELD	CHIEF EXECUTIVE OFFICER	40.00	Officer	$506,697	$54,667	$561,364
IAN LESSER	DIRECTOR FINANCE & ADMINISTRATION	40.00	Officer	$172,733	$42,983	$215,716
ANNA TURETSKY TO 724	PRINCIPAL, VENTURE INVESTMENTS	40.00	Key Emp	$327,122	$21,607	$348,729
REBECCA BISH-CORNELISSEN	HEAD DISCOVERY/PRE-CLINICAL RESEARCH	40.00	Highest	$310,646	$51,139	$361,785
AMY FEHIR	HEAD OF DEVELOPMENT	40.00	Highest	$215,995	$30,535	$246,530
REBECCA LIU	DIRECTOR, GRANTS ADMINISTRATION	40.00	Highest	$197,094	$34,568	$231,662
MICHAEL CARLETON	SENIOR SCIENTIFIC DIRECTOR	40.00	Highest	$175,776	$47,706	$223,482
ROBERT MAGIN	ASSOCIATE SCIENTIFIC DIRECTOR	40.00	Highest	$169,179	$20,443	$189,622

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2024	$44,772,901	$36,066,750	$105,459,714	$8,706,151
2023	$40,937,632	$35,209,497	$104,492,388	$5,728,135
2022	$55,345,494	$38,014,606	$110,652,350	$17,330,888
2021	$37,486,883	$35,686,709	$107,551,757	$1,800,174
2020	$40,176,299	$21,645,747	$109,005,993	$18,530,552
2019	$80,534,924	$47,346,929	$90,919,630	$33,187,995
2018	$40,519,118	$38,540,021	$33,818,430	$1,979,097

THE MARK FOUNDATION FOR CANCER RESEARCH (US) LTD